File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A translational research approach to poor treatment response in patients with schizophrenia: Clozapine-antipsychotic polypharmacy

TitleA translational research approach to poor treatment response in patients with schizophrenia: Clozapine-antipsychotic polypharmacy
Authors
Issue Date2009
PublisherCanadian Medical Association. The Journal's web site is located at http://www.cma.ca/index.cfm/ci_id/12267/la_id/1.htm
Citation
Journal Of Psychiatry And Neuroscience, 2009, v. 34 n. 6, p. 433-442 How to Cite?
AbstractPoor treatment response in patients with schizophrenia is an important clinical problem, and one possible strategy is concurrent treatment with more than one antipsychotic (polypharmacy). We analyzed the evidence base for this strategy using a translational research model focused on clozapine-antipsychotic polypharmacy (CAP). We considered 3 aspects of the existing knowledge base and translational research: the link between basic science and clinical studies of efficacy, the evidence for effectiveness in clinical research and the implications of research for the health care delivery system. Although a rationale for CAP can be developed from receptor pharmacology, there is little available preclinical research testing these concepts in animal models. Randomized clinical trials of CAP show minimal or no benefit for overall severity of symptoms. Most studies at the level of health services are limited to estimates of CAP prevalence and some suggestion of increased costs. Increasing use of antipsychotic polypharmacy in general may be a factor contributing to the underutilization of clozapine and long delays in initiating clozapine monotherapy. Translational research models can be applied to clinical questions such as the value of CAP. Better linkage between the components of translational research may improve the appropriate use of medications such as clozapine in psychiatric practice. © 2009 Canadian Medical Association.
Persistent Identifierhttp://hdl.handle.net/10722/81478
ISSN
2015 Impact Factor: 5.57
2015 SCImago Journal Rankings: 2.675
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHoner, WGen_HK
dc.contributor.authorProcyshyn, RMen_HK
dc.contributor.authorChen, EYHen_HK
dc.contributor.authorMacEwan, GWen_HK
dc.contributor.authorBarr, AMen_HK
dc.date.accessioned2010-09-06T08:18:15Z-
dc.date.available2010-09-06T08:18:15Z-
dc.date.issued2009en_HK
dc.identifier.citationJournal Of Psychiatry And Neuroscience, 2009, v. 34 n. 6, p. 433-442en_HK
dc.identifier.issn1180-4882en_HK
dc.identifier.urihttp://hdl.handle.net/10722/81478-
dc.description.abstractPoor treatment response in patients with schizophrenia is an important clinical problem, and one possible strategy is concurrent treatment with more than one antipsychotic (polypharmacy). We analyzed the evidence base for this strategy using a translational research model focused on clozapine-antipsychotic polypharmacy (CAP). We considered 3 aspects of the existing knowledge base and translational research: the link between basic science and clinical studies of efficacy, the evidence for effectiveness in clinical research and the implications of research for the health care delivery system. Although a rationale for CAP can be developed from receptor pharmacology, there is little available preclinical research testing these concepts in animal models. Randomized clinical trials of CAP show minimal or no benefit for overall severity of symptoms. Most studies at the level of health services are limited to estimates of CAP prevalence and some suggestion of increased costs. Increasing use of antipsychotic polypharmacy in general may be a factor contributing to the underutilization of clozapine and long delays in initiating clozapine monotherapy. Translational research models can be applied to clinical questions such as the value of CAP. Better linkage between the components of translational research may improve the appropriate use of medications such as clozapine in psychiatric practice. © 2009 Canadian Medical Association.en_HK
dc.languageengen_HK
dc.publisherCanadian Medical Association. The Journal's web site is located at http://www.cma.ca/index.cfm/ci_id/12267/la_id/1.htmen_HK
dc.relation.ispartofJournal of Psychiatry and Neuroscienceen_HK
dc.subject.meshAntipsychotic Agents - adverse effects - economics - therapeutic use-
dc.subject.meshClozapine - adverse effects - economics - therapeutic use-
dc.subject.meshPolypharmacy-
dc.subject.meshSchizophrenia - drug therapy - economics-
dc.subject.meshSchizophrenic Psychology-
dc.titleA translational research approach to poor treatment response in patients with schizophrenia: Clozapine-antipsychotic polypharmacyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1180-4882&volume=34 &issue=6&spage=433&epage=442&date=2009&atitle=A+translational+research+approach+to+poor+treatment+response+in+patients+with+schizophrenia:+clozapine-antipsychotic+polypharmacyen_HK
dc.identifier.emailChen, EYH: eyhchen@hku.hken_HK
dc.identifier.authorityChen, EYH=rp00392en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.pmid19949719-
dc.identifier.pmcidPMC2783434-
dc.identifier.scopuseid_2-s2.0-70449574214en_HK
dc.identifier.hkuros167740en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70449574214&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume34en_HK
dc.identifier.issue6en_HK
dc.identifier.spage433en_HK
dc.identifier.epage442en_HK
dc.identifier.isiWOS:000271193000003-
dc.publisher.placeCanadaen_HK
dc.identifier.scopusauthoridHoner, WG=7004460814en_HK
dc.identifier.scopusauthoridProcyshyn, RM=7003797939en_HK
dc.identifier.scopusauthoridChen, EYH=7402315729en_HK
dc.identifier.scopusauthoridMacEwan, GW=6604052646en_HK
dc.identifier.scopusauthoridBarr, AM=35474239200en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats